Scanner results now published to our DISCORD channel, Join Here: https://discord.gg/fTah76E3SE
Scanner results now published to our DISCORD channel, Join Here: https://discord.gg/fTah76E3SE
Thankyou to whoever submitted this entry! This was the first one ever submitted by someone else, I will have to check more often now!
What will we will expect from ASH (Dec. 10-13th, 2022):
Target: Level of Consistency/Efficacy
Duration of the drug: 28+ days
Patient Pool: 11 more (doubled data set of the targeted population)
Project Optimus: The management of CPK elevation and rhabo (important)
AI:
1. Roche/Genestech Collab. for fda- approved Erivedge:
Annual royality: 10 mill. avg. First-in-class orally administered small molecule Hedgehog
2. Q3: Assets without goodwill 113 mill. vs. 67 mill. liabilities – 12 mill. quarterburn (No offering till 2025) – market cap: 80.72 mill.
Focus: Emavusertib and a NDA submission (layoffed other projects)
4. 2023: Enrolling add. 9 patients (FDA) for 200/300 mg dose (early/mid next year)
Earning Transcript Q3 2022:
No information expressed or distributed by Black Ink Economics constitutes investment, trading, or financial advice. Black Ink Economics mission is to educate people on how to trade and to further their clients knowledge as to the workings of the financial markets and technical indicators. Any information presented or distributed by Black Ink Economics is for education and entertainment purposes only.
© Copyright 2024 — Black Ink Economics, Ltd. Legal
